<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The early occurrence of five cases of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in children treated for primary <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> on the Intergroup <z:hpo ids='HP_0002859'>Rhabdomyosarcoma</z:hpo> Study III (IRS III) has prompted this report </plain></SENT>
<SENT sid="1" pm="."><plain>These patients received <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and four received <z:chebi fb="0" ids="4911">etoposide</z:chebi> in addition to other agents </plain></SENT>
<SENT sid="2" pm="."><plain>There were 1,062 eligible patients entered on IRS III between 1984 and 1991 </plain></SENT>
<SENT sid="3" pm="."><plain>Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups </plain></SENT>
<SENT sid="4" pm="."><plain>Median follow-up time is 3.7 years (range 0-7.4 years) </plain></SENT>
<SENT sid="5" pm="."><plain>Incidence densities and odds ratios for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were calculated for various treatment groups </plain></SENT>
<SENT sid="6" pm="."><plain>Five cases of <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> have been reported through August 1992 </plain></SENT>
<SENT sid="7" pm="."><plain>A single case of <z:hpo ids='HP_0002669'>osteogenic sarcoma</z:hpo> was reported in the same period and a patient with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> has occurred since that time </plain></SENT>
<SENT sid="8" pm="."><plain>Median time to development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> was 39 months </plain></SENT>
<SENT sid="9" pm="."><plain>Incidence density of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> for patients receiving neither <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> nor <z:chebi fb="0" ids="4911">etoposide</z:chebi> was 0, for those receiving <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> but no <z:chebi fb="0" ids="4911">etoposide</z:chebi> it was 7.6, and when both agents were given, it was 51.6 </plain></SENT>
<SENT sid="10" pm="."><plain>The odds ratios of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> for the latter two groups indicated a risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> which was seven times higher in the patients who received both agents </plain></SENT>
<SENT sid="11" pm="."><plain>A history of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> was present in <z:hpo ids='HP_0000001'>all</z:hpo> five families of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and several other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> had occurred in three families </plain></SENT>
<SENT sid="12" pm="."><plain>Preliminary analysis suggests a possible causal role for low-dose <z:chebi fb="0" ids="4911">etoposide</z:chebi> in addition to that assumed for <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> in the early development of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> among pediatric patients treated for <z:hpo ids='HP_0002859'>rhabdomyosarcoma</z:hpo> </plain></SENT>
</text></document>